20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases

Author(s): Osama H. Elshenawy, Anwar Anwar-Mohamed, Ayman O.S. El-Kadi

Journal Name: Current Drug Metabolism

Volume 14 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


Arachidonic acid (AA) is metabolized by enzymes of the cytochrome P450 (CYP) 4A and CYP4F subfamilies to 20- hydroxyeicosatetraeonic acid (20-HETE), which plays an important role in the cardiovascular system. In the current work, we reviewed the formation of 20-HETE in different species by different CYPs; 20-HETE metabolism by cyclooxygenases (COXs) and different isomerases; and the current available inducers and inhibitors of 20-HETE formation in addition to its agonists and antagonists. Moreover we reviewed the negative role of 20-HETE in cardiac hypertrophy, cardiotoxicity, diabetic cardiomyopathy, and in ischemia/reperfusion (I/R) injury. Lastly, we reviewed the role of 20-HETE in different hypertension models such as the renin/angiotensin II model, Goldblatt model, spontaneously hypertensive rat model, androgen-induced model, slat- and deoxycorticosterone acetate (DOCA)-salt-induced models, and high fat diet model. 20-HETE can affect pro- and anti-hypertensive mechanisms dependent upon where, when, and by which isoform it has been produced. In contrast to hypertension we also reviewed the role of 20-HETE in endotoxin-induced hypotension and the natriuretic effects of 20-HETE. Based on the recent studies, 20-HETE production and/or action might be a therapeutic target to protect against the initiation and progression of cardiovascular diseases.

Keywords: Cytochrome P450s (CYPs), 20-hydroxyeicosatetraeonic acid (20-HETE), Arachidonic acid (AA), Cardiovascular diseases.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [706 - 719]
Pages: 14
DOI: 10.2174/1389200211314060007
Price: $65

Article Metrics

PDF: 29